Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
Colorcon
Express Scripts
McKinsey
Moodys

Last Updated: December 2, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ZANUBRUTINIB

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for zanubrutinib

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02569476 ↗ BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies Completed BeiGene Phase 1 2016-01-13 This study evaluated the safety and preliminary efficacy of BGB-3111 (zanubrutinib) in combination with obinutuzumab in participants with B-cell lymphoid malignancies.
NCT02795182 ↗ Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies Completed BeiGene Phase 1 2016-06-29 This study is evaluating the safety and preliminary efficacy of BGB-3111 in combination with BGB-A317 in participants with B-cell lymphoid malignancies.
NCT02914938 ↗ A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma Recruiting Clinipace LTD Phase 1 2016-10-01 A Three-Arm Study of ME-401 in Subjects with Relapsed/Refractory CLL/SLL or FL, of ME-401 in Combination with Rituximab in Subjects with Relapsed/Refractory CLL/SLL or B-cell NHL, and of ME-401 in Combination with Zanubrutinib in Subjects with Relapsed/Refractory CLL/SLL or B-cell NHL
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for zanubrutinib

Condition Name

Condition Name for zanubrutinib
Intervention Trials
Mantle Cell Lymphoma 7
Small Lymphocytic Lymphoma 6
Diffuse Large B Cell Lymphoma 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for zanubrutinib
Intervention Trials
Lymphoma 31
Leukemia, Lymphocytic, Chronic, B-Cell 12
Lymphoma, Large B-Cell, Diffuse 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for zanubrutinib

Trials by Country

Trials by Country for zanubrutinib
Location Trials
United States 157
China 130
Australia 57
United Kingdom 19
Japan 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for zanubrutinib
Location Trials
Texas 11
New York 10
New Jersey 10
Florida 10
California 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for zanubrutinib

Clinical Trial Phase

Clinical Trial Phase for zanubrutinib
Clinical Trial Phase Trials
Phase 3 8
Phase 2 26
Phase 1/Phase 2 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for zanubrutinib
Clinical Trial Phase Trials
Recruiting 29
Completed 13
Not yet recruiting 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for zanubrutinib

Sponsor Name

Sponsor Name for zanubrutinib
Sponsor Trials
BeiGene 29
University of California, San Diego 3
Peking Union Medical College Hospital 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for zanubrutinib
Sponsor Trials
Industry 37
Other 27
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Harvard Business School
Baxter
Moodys
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.